alirocumab

REMS

Primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) (as adjunct to diet, as monotherapy or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies [e.g. statin, ezetimibe]).
Reduction in risk of MI, stroke, and unstable angina requiring hospitalization in patients with established cardiovascular disease.
Homozygous familial hypercholesterolemia (HoFH) (as adjunct to other LDL-C lowering therapies).

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Serious hypersensitivity.

Use Cautiously in:

Severe renal impairment;
Severe hepatic impairment;
OB: Safety not established in pregnancy;
Lactation: Safety not established in breastfeeding;
Pedi: Safety and effectiveness not established in children;
Geri: Older adults may be more sensitive to drug effects.

Adv. Reactions/Side Effects ⬆ ⬇

Local: injection site reactions

Neuro: confusion

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA, VASCULITIS)

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Solution for injection (prefilled pens): 75 mg/mL; 150 mg/mL

Route/Dosage ⬆ ⬇

Primary Hyperlipidemia (including Heterozygous Familial Hypercholesterolemia) or Established Cardiovascular Disease

SC (Adults ): 75 mg every 2 wk or 300 mg every 4 wk; if desired LDL-C has not been achieved, may ↑ dose to 150 mg every 2 wk. Patients with HeFH undergoing apheresis: 150 mg every 2 wk.

Homozygous Familial Hypercholesterolemia

SC (Adults ): 150 mg every 2 wk.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

A human monoclonal immunoglobulin (IgG1) produced in genetically engineered Chinese hamster ovary cells that binds to PCSK9, inhibiting its binding to the low density lipoprotein receptor (LDLR) resulting in ↑ number of LDLRs available to clear LDL from blood.

Therapeutic effects:

Reduction in LDL-C in primary hyperlipidemia and HoFH.
Reduction in risk of MI, stroke, and unstable angina requiring hospitalization.

Classifications ⬆ ⬇

Therapeutic Classification: lipid-lowering agents

Pharmacologic Classification: proprotein convertase subtilisin kexin type-9 pcsk-9 inhibitors, monoclonal antibodies

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed (85%) following SUBQ administration.

Distribution: Mostly distributed in the circulatory system.

Metabolism/Excretion: Eliminated by binding to PCSK9 and by proteolytic degradation.

Half-Life: 17–20 days.

Time/Action Profile ⬆ ⬇

(effect on circulating unbound PCSK9)

ROUTE	ONSET	PEAK	DURATION
SUBQ	rapid	4–8 hr	2 wk

Patient/Family Teaching ⬆ ⬇

Instruct patient in correct technique for self-injection, care and disposal of equipment. Administer missed doses within 7 days, then resume original schedule. If not administered within 7 days, wait until next dose on original schedule. Advise patient to read Patient Information before starting therapy and with each Rx refill in case of changes.
Advise patient that this medication should be used in conjunction with diet restrictions (fat, cholesterol, carbohydrates, alcohol), exercise, and cessation of smoking.
Advise patient to notify health care professional immediately if signs and symptoms of hypersensitivity reactions occur.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking any other Rx, OTC, or herbal products.
Advise patient to notify health care professional of medication regimen prior to treatment or surgery.
Rep: Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding. There is a pregnancy safety study for alirocumab. If alirocumab is administered during pregnancy, report alirocumab exposure by contacting Regeneron at 1-844-734-6643.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0024- Sanofi-Aventis U.S. LLC
- 0024-5901- Praluent
  - 0024-5901-00- 1 SYRINGE, GLASS in 1 CARTON (0024-5901-00) > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5901- Praluent
  - 0024-5901-01- 1 SYRINGE, GLASS in 1 CARTON (0024-5901-01) > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5901- Praluent
  - 0024-5901-02- 2 SYRINGE, GLASS in 1 CARTON (0024-5901-02) > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5902- Praluent
  - 0024-5902-00- 1 SYRINGE, GLASS in 1 CARTON (0024-5902-00) > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5902- Praluent
  - 0024-5902-01- 1 SYRINGE, GLASS in 1 CARTON (0024-5902-01) > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5902- Praluent
  - 0024-5902-02- 2 SYRINGE, GLASS in 1 CARTON (0024-5902-02) > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5903- Praluent
  - 0024-5903-00- 1 BLISTER PACK in 1 CARTON (0024-5903-00) > 1 SYRINGE, GLASS in 1 BLISTER PACK > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5903- Praluent
  - 0024-5903-01- 1 BLISTER PACK in 1 CARTON (0024-5903-01) > 1 SYRINGE, GLASS in 1 BLISTER PACK > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5903- Praluent
  - 0024-5903-02- 2 BLISTER PACK in 1 CARTON (0024-5903-02) > 1 SYRINGE, GLASS in 1 BLISTER PACK > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5904- Praluent
  - 0024-5904-00- 1 BLISTER PACK in 1 CARTON (0024-5904-00) > 1 SYRINGE, GLASS in 1 BLISTER PACK > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5904- Praluent
  - 0024-5904-01- 1 BLISTER PACK in 1 CARTON (0024-5904-01) > 1 SYRINGE, GLASS in 1 BLISTER PACK > 1 mL in 1 SYRINGE, GLASS

0024- Sanofi-Aventis U.S. LLC
- 0024-5904- Praluent
  - 0024-5904-02- 2 BLISTER PACK in 1 CARTON (0024-5904-02) > 1 SYRINGE, GLASS in 1 BLISTER PACK > 1 mL in 1 SYRINGE, GLASS

72733- Sanofi US Corporation
- 72733-5901- Praluent
  - 72733-5901-2- 2 SYRINGE, GLASS in 1 CARTON (72733-5901-2) > 1 mL in 1 SYRINGE, GLASS

72733- Sanofi US Corporation
- 72733-5902- Praluent
  - 72733-5902-2- 2 SYRINGE, GLASS in 1 CARTON (72733-5902-2) > 1 mL in 1 SYRINGE, GLASS

section name header

Indications ⬇